LoadingLoadingLoadingThe quick read
Latest quote·Oct 16
Net selling: insiders sold $1.3M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $1K to $15K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $1.3M and bought $0 of BDX stock on the open market in the 90 days to Oct 18, 2026, according to SEC Form 4 filings. $825K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Polen, Thomas E Jr (Chairman, CEO and President), who sold $768K. The latest filing was on Sep 30, 2026.
Rep. Thomas H. Kean Jr sold $1K to $15K on May 21, 2026, disclosed 28 days later. In total, 1 member disclosed 1 BDX trade with trade dates in the last 180 days, filed a median 28 days after trading.
This summary uses filings available on Oct 18, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net selling.
Buys/Adds (1)
Balyasny
$47.3M
added
Sells/Trims (2)
Citadel
$112.4M
trimmed
Starboard Value
$100.1M
sold
Sells (2)
No tracked top-trader positions in BDX right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Aug 6, 2026
Financial period
Q3 FY2026
Adjusted EPS
$3.14 expected
Revenue
$4.89B expected
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 6, 2026 | $3.23 / $3.14Yahoo Finance | +2.93% beat | $4.98B / $4.89B | +1.91% beat |
| Mar 31, 2026 | May 7, 2026 | $2.90 / $2.77Yahoo Finance | +4.51% beat | $4.71B / Unavailable | Unavailable |
| Dec 31, 2025 | Feb 9, 2026 | $2.91 / $2.81Yahoo Finance | +3.47% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 6, 2025 | $3.96 / $3.91Yahoo Finance | +1.15% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 7, 2025 | $3.68 / $3.40Alpha Vantage | +8.24% beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 1, 2025 | $3.35 / $3.28Alpha Vantage | +2.13% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 5, 2025 | $3.43 / $2.99Alpha Vantage | +14.72% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 7, 2024 | $3.81 / $3.77Alpha Vantage | +1.06% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 17, 2026
EPS expected
$4.03 to $4.12
Revenue expected
8 analysts
Last 30 days
Analysts cutting estimates
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $5.89B | $5.25B | $4.71B | $4.98B |
| Cost of what it sold | $3.09B | $2.91B | $2.56B | $2.67B |
| Gross profit | $2.80B | $2.34B | $2.15B | $2.31B |
| What it spent | ||||
| Research and development | $322.0M | $318.0M | $249.0M | $258.0M |
| Sales and admin | $1.37B | $1.43B | $1.21B | $1.26B |
| Other operating costs | $414.0M | — | $599.0M | $133.0M |
| Total operating expenses | $2.10B | $1.75B | $2.06B | $1.65B |
| What was left | ||||
| Operating profit | $697.0M | $594.0M | $94.0M | $663.0M |
| Interest on debt | $155.0M | $107.0M | $149.0M | $132.0M |
| Profit before tax | $510.0M | $487.0M | $39.0M | $554.0M |
| Tax | $17.0M | $105.0M | $76.0M | $103.0M |
| Net profit | $493.0M | $382.0M | -$311.0M | $377.0M |
| EBITDA | $1.29B | $1.21B | $709.0M | $1.25B |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Quest Diagnostics Incorporated (DGX) stock price, news, quote and history
Leans bullishOct 14Becton, Dickinson and Company Yields 2.4%: Is Its Valuation Finally Worth a Look?
Leans bullishOct 14West Pharmaceutical Services (WST) Heads To CPHI Milan As Undervalued Narrative Holds
NeutralOct 14Becton Dickinson & Co. stock outperforms competitors on strong trading day
BullishOct 12Weekly Recap: $19B U.S. investment and undisclosed agreement impact
BullishOct 12Operating cash flow per share of Becton, Dickinson and Company – HAN:BOX
NeutralOct 12Urology Devices Market to Exceed $56 billion by 2030 at 7% CAGR, Medtronic Leads, Consumables 31%
Leans bullishOct 12Ferass Abuzaina named Worldwide President of Surgery at BD
BullishOct 9